Skip to main content
Erschienen in: Diabetologia 8/2012

01.08.2012 | Commentary

The rise and fall of HbA1c as a risk marker for diabetes complications

verfasst von: E. S. Kilpatrick

Erschienen in: Diabetologia | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

It is still unclear whether short-term, within-day, variability in glycaemic control is contributory to the development of diabetes micro- or macrovascular complications. However, consistent and compelling data are emerging that longer term fluctuations in glucose, as evidenced by increases in HbA1c variability, do indeed add to the mean HbA1c value in predicting the risk of microvascular disease. Until now, studies have found this to be the case mainly in type 1 diabetes, but in this issue of Diabetologia (DOI: 10.​1007/​s00125-012-2572-7) an analysis of the Tsukuba Kawai Diabetes Registry in Japan has found that HbA1c variability also predicts the risk of nephropathy in type 2 diabetic patients. These observations raise the possibility that reducing rises and falls in HbA1c may help avoid hyperglycaemia-related vascular disease without running the same risk of hypoglycaemia that a strategy focusing purely on lower HbA1c might incur.
Literatur
1.
Zurück zum Zitat Sugawara A, Kawai K, Motohashi S (2012) HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia. doi:10.1007/s00125-012-2572-7 Sugawara A, Kawai K, Motohashi S (2012) HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia. doi:10.​1007/​s00125-012-2572-7
2.
Zurück zum Zitat Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef
3.
Zurück zum Zitat Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901PubMedCrossRef
4.
Zurück zum Zitat Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JBL, DeVries JH (2009) Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229–2232PubMedCrossRef Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JBL, DeVries JH (2009) Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229–2232PubMedCrossRef
5.
Zurück zum Zitat Home PD (2005) Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989–998PubMedCrossRef Home PD (2005) Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989–998PubMedCrossRef
6.
Zurück zum Zitat Raz I, Wilson PWF, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381–386PubMedCrossRef Raz I, Wilson PWF, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381–386PubMedCrossRef
7.
Zurück zum Zitat Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 31:2198–2202PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 31:2198–2202PubMedCrossRef
8.
Zurück zum Zitat Wadèn J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, Finnish Diabetic Nephropathy Study Group (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef Wadèn J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, Finnish Diabetic Nephropathy Study Group (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef
9.
Zurück zum Zitat Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011–1013PubMedCrossRef Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011–1013PubMedCrossRef
10.
Zurück zum Zitat Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569CrossRef Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569CrossRef
11.
Zurück zum Zitat Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef
12.
Zurück zum Zitat Ihnat M, Thorpe J, Ceriello A (2007) Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med 24:582–586PubMedCrossRef Ihnat M, Thorpe J, Ceriello A (2007) Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med 24:582–586PubMedCrossRef
13.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
14.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef
15.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116:874–886 The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116:874–886
16.
Zurück zum Zitat Bolen SD, Bricker E, Samuels TA et al (2009) Factors associated with intensification of oral diabetes medications in primary care provider–patient dyads: a cohort study. Diabetes Care 32:25–31PubMedCrossRef Bolen SD, Bricker E, Samuels TA et al (2009) Factors associated with intensification of oral diabetes medications in primary care provider–patient dyads: a cohort study. Diabetes Care 32:25–31PubMedCrossRef
Metadaten
Titel
The rise and fall of HbA1c as a risk marker for diabetes complications
verfasst von
E. S. Kilpatrick
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 8/2012
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2610-5

Weitere Artikel der Ausgabe 8/2012

Diabetologia 8/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.